Last updated: August 9, 2026
Sanofi Pasteur SA, now operating within Sanofi’s Vaccines business, is one of the largest global vaccine manufacturers. Its competitive position rests on scale, manufacturing capacity, public-sector procurement relationships, pediatric franchises, influenza products, travel vaccines and its commercial partnership with AstraZeneca for Beyfortus, a monoclonal antibody that prevents respiratory syncytial virus, or RSV, disease in infants.
Sanofi’s vaccine business generated approximately €7.5 billion in sales in 2023 and remained one of the company’s core growth platforms.[1] The business has stronger commercial and manufacturing defenses than patent defenses. Many mature vaccines face limited composition-of-matter protection because their underlying antigens and technologies are long established. Market access, regulatory approvals, manufacturing validation, supply reliability, public tenders and clinical data are often more important than patent term.
What is Sanofi Pasteur SA’s market position in vaccines?
Sanofi Pasteur SA is a global vaccine operating entity associated with Sanofi’s Vaccines division. Sanofi sells vaccines in more than 150 countries and maintains production and distribution capabilities across North America, Europe and emerging markets.[1]
Its market position is strongest in:
- Seasonal influenza vaccines
- Pediatric combination vaccines
- Meningococcal vaccines
- Tetanus, diphtheria and pertussis vaccines
- Polio vaccines
- Travel and endemic-disease vaccines
- RSV prevention through Beyfortus
The company competes with Pfizer, GSK, Merck & Co., Moderna, CSL Seqirus, AstraZeneca and Bharat Biotech, depending on the product and geography.
Sanofi Vaccines revenue exposure
Sanofi reports vaccines as a separate business within its Specialty Care, Vaccines and General Medicines reporting structure. Key commercial drivers include influenza season severity, government procurement, pediatric birth cohorts, immunization schedules, product availability and public-health policy.
| Business area |
Representative products |
Primary competitors |
Commercial characteristics |
| Influenza |
Fluzone, Flublok |
CSL Seqirus, GSK, AstraZeneca |
Large seasonal tenders and recurring annual demand |
| Pediatric combinations |
Vaxelis, Pentacel |
GSK, Pfizer, Merck |
Institutional purchasing and national schedules |
| Meningococcal |
MenQuadfi, Menactra in legacy markets |
Pfizer, GSK |
School-age and adolescent immunization demand |
| Tdap |
Adacel |
GSK, Pfizer |
Adult boosters, pregnancy and public programs |
| Polio |
IPOL |
Bilthoven Biologicals, Bharat Biotech |
Public-sector and travel demand |
| Travel vaccines |
YF-VAX, Typhim Vi |
Valneva, Bharat Biotech |
Travel recovery and endemic-area procurement |
| RSV prevention |
Beyfortus |
AstraZeneca, Pfizer, GSK |
Infant immunization and seasonal public-health programs |
Sanofi’s scale gives it a meaningful advantage in government contracts and supply planning. The company’s exposure to mature products also creates pricing pressure, especially where tenders treat vaccines as interchangeable or where national procurement agencies prioritize lowest cost.
Which companies compete with Sanofi Pasteur SA?
Sanofi faces different competitors by vaccine class rather than one universal rival.
GSK
GSK is Sanofi’s closest broad-based competitor in vaccines. GSK has major positions in shingles, meningococcal disease, influenza, pediatric vaccines and RSV prevention. Its Arexvy vaccine gives it a leading position in older-adult RSV vaccination, while Sanofi’s principal RSV growth asset is Beyfortus for infants.
Pfizer
Pfizer competes with Sanofi in pneumococcal disease, meningococcal disease, pediatric vaccines and RSV. Abrysvo gives Pfizer a direct position in adult and maternal RSV markets. Pfizer’s Prevnar franchise is substantially more important in pneumococcal vaccines than Sanofi’s current portfolio.
CSL Seqirus
CSL Seqirus is a major influenza competitor with substantial government procurement exposure. Its differentiated influenza products and manufacturing footprint create direct competition with Fluzone and Flublok.
Merck & Co.
Merck is strongest in human papillomavirus vaccination through Gardasil and in several pediatric and adult categories. It is not a direct competitor to Sanofi across the entire portfolio but has greater concentration in high-value HPV products.
Moderna
Moderna competes in mRNA COVID-19 vaccines and has a pipeline covering influenza, RSV and other respiratory diseases. Its threat to Sanofi is greater in next-generation respiratory vaccines than in Sanofi’s legacy pediatric and travel portfolio.
What products and technologies are protected by Sanofi vaccine patents?
Sanofi’s vaccine intellectual property includes product claims, antigen combinations, adjuvants, manufacturing processes, purification methods, stabilizers, delivery systems, analytical assays and use claims.
The highest-value protected areas are generally:
- Combination vaccine formulations.
- Recombinant influenza production and purification.
- Adjuvant systems and antigen presentation.
- Stabilized antigen compositions.
- Manufacturing cell lines and production processes.
- Ready-to-use presentations, containers and delivery devices.
- Methods for preventing disease in defined age groups or risk populations.
Patent protection varies materially by product. Older vaccines such as IPOL, Adacel and several pediatric combinations rely more heavily on manufacturing know-how, regulatory history, trademarks and supply contracts than on long-lived core patents.
Formulation and manufacturing barriers
Vaccine manufacturing creates barriers that can persist after core patents expire. A competing manufacturer generally must establish:
- A validated production process
- Consistent antigen yield
- Control of impurities and residual contaminants
- Potency and stability specifications
- Sterility assurance
- Cold-chain performance
- Comparability or bridging data
- Site-specific regulatory approval
- Commercial-scale batch reliability
These requirements make vaccine competition slower than conventional small-molecule generic entry. A biosimilar-style pathway is not directly applicable to most traditional vaccines, although biological comparability and manufacturing similarity remain important regulatory concepts.
When does Sanofi Pasteur lose exclusivity?
Sanofi does not have one portfolio-wide exclusivity date. Each vaccine has separate patent, regulatory, trademark and procurement circumstances.
Regulatory exclusivity and patent timing
The United States generally does not treat all vaccines like new chemical entities listed in the Orange Book. Many vaccines are licensed as biological products under the Public Health Service Act or as products subject to biologics regulations. Patent listing can occur in the FDA’s Purple Book for applicable biological products, while conventional Orange Book listings are more relevant to drug products and certain drug-device combinations.[2,3]
For Sanofi vaccines, the practical loss of exclusivity usually occurs through one of four events:
- A competing vaccine receives FDA, EMA or other national approval.
- A rival wins a government or institutional tender.
- A substitute vaccine demonstrates comparable clinical utility.
- A manufacturing or process patent expires without a replacement barrier.
The company’s mature vaccines generally have limited visibility into a single, reliable “generic launch date.” Market entry depends on the regulatory category, manufacturing capability and procurement cycle.
What is the Orange Book status of Sanofi Pasteur vaccines?
Sanofi’s vaccine portfolio is not uniformly represented in the FDA Orange Book. The Orange Book identifies approved drug products and certain patent and exclusivity information, while biological products are generally tracked through the Purple Book and related FDA biologics records.[2,3]
A product-by-product review is required because Sanofi may hold:
- A biologics license application, or BLA
- A new drug application, or NDA
- A supplemental approval
- A combination-product approval
- Device-related protection
- Process patents that are not directly reflected in standard product listings
Beyfortus is a biologic monoclonal antibody and is evaluated under the biologics framework. It is not a conventional small-molecule generic product. Fluzone and other influenza products have their own regulatory histories and may be updated annually or seasonally.
Which patents protect Beyfortus and Sanofi’s RSV strategy?
Beyfortus, or nirsevimab, was developed by AstraZeneca and commercialized with Sanofi. The principal commercial rights are governed by the collaboration agreement rather than ownership by Sanofi Pasteur SA alone.
Beyfortus is a long-acting monoclonal antibody targeting the RSV fusion protein. Its competitive protection includes:
- Antibody sequence and sequence variants
- Binding to the RSV F protein
- Neutralization and prophylactic use
- Extended half-life technology
- Dosing and administration
- Pediatric prevention indications
- Manufacturing and formulation methods
The antibody’s modified half-life is a key technical differentiator because it supports single-dose seasonal protection for many infants. The product competes with Pfizer’s Abrysvo, which is a vaccine for adults and maternal immunization rather than a directly identical infant monoclonal antibody product.
Beyfortus’ market protection is stronger than that of many mature Sanofi vaccines because of its newer biologic technology, recent regulatory approvals and pediatric clinical data. Its principal risks are manufacturing scale-up, payer adoption, government procurement, competing maternal vaccination programs and future long-acting antibodies.
How strong is Sanofi Pasteur SA’s patent estate?
Sanofi’s patent estate is strong at the portfolio level but uneven by asset.
| Protection category |
Relative strength |
Assessment |
| Mature vaccine composition patents |
Low to moderate |
Many core technologies are old or broadly known |
| Combination formulations |
Moderate |
Claims can protect specific antigen combinations and ratios |
| Manufacturing processes |
Moderate to strong |
Process complexity can deter rapid competition |
| Adjuvants and delivery systems |
Moderate |
Strength depends on claim scope and reproducibility |
| Beyfortus biologic technology |
Stronger |
Newer antibody, dosing and manufacturing claims |
| Trademarks and brand recognition |
Strong |
Relevant in retail, travel and private-market channels |
| Regulatory and clinical data |
Strong |
Especially important for pediatric and RSV products |
| Supply and tender position |
Strong |
A major defense in public immunization markets |
The main risk to patent strength is that broad vaccine claims can face validity challenges if they rely on known antigens, predictable combinations or established manufacturing approaches. Narrow process claims may be difficult to enforce against an independently developed production method.
Are there Paragraph IV challenges against Sanofi vaccines?
Paragraph IV litigation is more common for small-molecule drugs than for vaccines. A generic applicant may challenge patents listed for an eligible drug product by filing an Abbreviated New Drug Application with a Paragraph IV certification. Traditional vaccines and biologic products generally proceed through different regulatory pathways.
Potential challengers to Sanofi products are more likely to use:
- A separate biologics license application
- A stand-alone vaccine approval
- A competing recombinant or cell-based influenza product
- A tender-based substitution strategy
- Patent invalidity or non-infringement litigation
- Biosimilar or interchangeable-product procedures where legally applicable
This reduces the value of relying solely on Paragraph IV monitoring when assessing Sanofi’s competitive risk. FDA approvals, Purple Book records, patent litigation dockets, procurement awards and manufacturing announcements provide a better risk signal.
What patent litigation affects Sanofi Pasteur?
Sanofi has faced intellectual-property disputes across its pharmaceutical portfolio, but vaccine-specific litigation is less consistently disclosed as a central commercial risk than disputes involving major small-molecule or biologic medicines.
Vaccine-related legal exposure can arise from:
- Antigen or antibody patents
- Adjuvant technology
- Cell-based or recombinant manufacturing
- Combination vaccine formulation
- Delivery devices and prefilled syringes
- Trade secrets and manufacturing know-how
- Licensing rights from collaborators
For Beyfortus, the AstraZeneca-Sanofi collaboration creates a separate contractual and licensing dimension. Any dispute could affect commercialization rights, royalty economics, development obligations or geographic rights even if the underlying patent case does not directly involve Sanofi Pasteur SA.
What licensing deals shape Sanofi’s vaccine strategy?
The AstraZeneca-Sanofi collaboration for nirsevimab is the most commercially significant external relationship in the current vaccine portfolio. AstraZeneca contributed the antibody program and related development assets, while Sanofi took a leading role in commercialization and global expansion.[4]
The agreement gives Sanofi access to an RSV prevention product without requiring sole ownership of the underlying discovery platform. It also distributes development, manufacturing and commercial risk between the parties.
Sanofi has used other partnerships and licensing arrangements across vaccines, including collaborations for pediatric combination products and regional commercialization. The strategic pattern is consistent: retain manufacturing and commercial scale while acquiring access to technologies that would take longer to develop internally.
What generic and biosimilar entry risks exist for Sanofi?
Sanofi’s greatest entry risk is not a conventional generic wave. It is substitution by products with better delivery, broader indications, improved efficacy or lower public-sector pricing.
Generic entry scenarios
The most plausible scenarios are:
- A competing influenza product wins tenders through price or supply reliability.
- A new meningococcal vaccine displaces an older Sanofi product.
- A rival pediatric combination reduces Sanofi’s share in national schedules.
- A biosimilar or follow-on antibody competes with Beyfortus after relevant exclusivities expire.
- Maternal RSV vaccination reduces the addressable market for infant prophylaxis.
- Next-generation mRNA vaccines challenge established influenza platforms.
Manufacturing scale creates a meaningful entry barrier, but it does not prevent product replacement. Public procurement agencies can switch suppliers when clinical requirements are met and supply security improves.
How does Sanofi compare with GSK, Pfizer and Moderna?
| Company |
Primary vaccine strength |
Patent profile |
Main threat to Sanofi |
| Sanofi |
Influenza, pediatric, meningococcal, travel and RSV infant prevention |
Broad but mixed; manufacturing and regulatory defenses are important |
Exposure to mature products and tender pricing |
| GSK |
Shingles, meningococcal, influenza, RSV older adults |
Stronger newer-product concentration |
Direct competition across respiratory and pediatric vaccines |
| Pfizer |
Pneumococcal, RSV, meningococcal |
Strong commercial franchises and newer biologic assets |
Superior position in pneumococcal and maternal RSV |
| Moderna |
mRNA COVID-19 and respiratory pipeline |
Platform and sequence-based protection |
Potential disruption in influenza and RSV |
| CSL Seqirus |
Influenza |
Process, platform and product-specific protection |
Direct pressure on Sanofi influenza sales |
| Merck |
HPV and selected pediatric products |
Strong HPV franchise |
Category concentration outside Sanofi’s core areas |
Sanofi has one of the broadest portfolios, but GSK and Pfizer have stronger positions in selected high-value franchises. Moderna is the most significant platform-based disruptor because its mRNA technology could alter vaccine development timelines and manufacturing economics.
What is Sanofi Pasteur’s geographic coverage?
Sanofi sells vaccines across North America, Europe, Latin America, Asia-Pacific, Africa and the Middle East. Geographic strength is particularly important in:
- U.S. government influenza procurement
- European pediatric and adult immunization programs
- Travel vaccines in North America and Europe
- Emerging-market public-health campaigns
- RSV prevention programs in countries establishing infant immunization policies
Geographic patent coverage is less important than regulatory approval and local manufacturing access for many vaccines. Sanofi’s commercial position depends on country-specific tenders, reimbursement, national schedules and local supply requirements.
What is the FDA regulatory status of Sanofi’s key vaccines?
Sanofi’s products are regulated under different FDA pathways. Fluzone products have seasonal regulatory updates and multiple presentations. Flublok is a recombinant influenza vaccine. Vaxelis is a pediatric combination vaccine marketed through a partnership structure. Beyfortus is a licensed biologic for prevention of RSV lower respiratory tract disease in specified infant populations.[5]
Regulatory risk includes:
- Annual strain-selection and manufacturing requirements for influenza
- Expanded age-group indications
- Postmarketing safety obligations
- Manufacturing-site inspections
- Supply shortages
- Label changes
- Pediatric immunization recommendations
- Competition between maternal vaccination and infant prophylaxis
Key Takeaways
- Sanofi Pasteur SA is part of Sanofi’s global Vaccines business and has a leading position in influenza, pediatric, meningococcal, travel and RSV prevention products.
- Sanofi’s portfolio-level strength is greater than its individual-product patent strength.
- Mature vaccines rely heavily on manufacturing expertise, regulatory approvals, trademarks and procurement relationships.
- Beyfortus is the most important newer strategic asset associated with Sanofi’s vaccine business, but AstraZeneca retains a central role in the collaboration.
- Orange Book analysis alone does not capture Sanofi’s vaccine exclusivity. Purple Book records, FDA biologics data, patent databases, litigation dockets and government tenders are also relevant.
- Paragraph IV risk is less central than independent biologic entry, competing vaccine approvals and tender substitution.
- GSK and Pfizer are the closest broad competitors. CSL Seqirus is the principal direct influenza competitor, while Moderna represents the largest platform-driven disruption risk.
- Sanofi’s main commercial vulnerabilities are mature-product pricing, annual influenza volatility, government procurement concentration and replacement by newer vaccine technologies.
FAQs About Sanofi Pasteur SA’s Vaccine Patent and Competitive Position
Does Sanofi Pasteur still operate as a separate company?
Sanofi Pasteur remains associated with Sanofi’s vaccine operations and legal entities, but Sanofi publicly presents the business primarily as its Vaccines division rather than as an independent listed company.
Is Beyfortus owned by Sanofi or AstraZeneca?
Beyfortus was developed by AstraZeneca and is commercialized globally through a collaboration with Sanofi. Rights, economics and responsibilities depend on the applicable territory and agreement terms.
Can a generic company copy Sanofi’s vaccines after patent expiration?
A competitor cannot rely on patent expiration alone. It generally must obtain the required regulatory approval, validate manufacturing, demonstrate product quality and secure commercial distribution or tender access.
Does Sanofi have the strongest influenza vaccine patent portfolio?
Sanofi has a major influenza commercial position, but patent strength varies by product. CSL Seqirus, GSK and newer recombinant or mRNA developers may hold stronger protection for particular platforms or formulations.
Will maternal RSV vaccination reduce Beyfortus sales?
Maternal vaccination can reduce the number of infants requiring antibody prophylaxis, but the commercial effect depends on maternal coverage, recommendations, contraindications, timing, country policy and payer decisions.
References
-
Sanofi. (2024). 2023 annual report: Universal registration document and annual financial report. Sanofi.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
AstraZeneca. (2023). Annual report and Form 20-F. AstraZeneca PLC.
-
U.S. Food and Drug Administration. (2023). FDA approves new drug to prevent RSV in infants and children. U.S. Department of Health and Human Services.
